Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyAnthem IL-6 Inhibitor Coverage Update | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedAnthemPolicy CC-0066

    Monoclonal Antibodies to Interleukin-6

    Customize your policy alerts

    Sign up for Anthem Policy CC-0066 alerts

    Get alerted when Policy CC-0066 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage criteria, quantity limits, and prior authorization requirements for IL-6 receptor monoclonal antibodies (tocilizumab products and sarilumab) across multiple indications including RA, GCA, JIA, CRS, SSc-ILD, transplant rejection, and others for Anthem members.

    Policy Summary
    PayerAnthem
    PolicyMonoclonal Antibodies to Interleukin-6
    Policy CodePolicy CC-0066
    Change TypeRevised — coding and clinical updates
    Effective Date03/26/2026
    Last ReviewFeb 20, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for initial and continuation requests and include indication-specific documentation (diagnosis, prior therapies, and product-specific details).
    SourceLink
    POLICY UPDATE CHANGES

    Removed Tyenne from certain HCPCS (M0235, M0236 and Q0235) and later added HCPCS Q0238, M0233, and M0234 for Tyenne effective 4/1/26.

    Updated tocilizumab criteria to include additional NCCN recommendations and expanded pediatric COVID-19 approvals; updated biosimilar step therapy and convenience notes.

    Added HCPCS codes M0233-M0250 and Q0235-Q0249 for IV and injection administration of tocilizumab products for hospitalized COVID-19 patients meeting steroid and oxygenation requirements.

    >10Indications
    MultipleHCPCS updates
    8 mg/kgIV dose limit
    4/28dActemra subQ limit
    2/28dKevzara subQ limit
    02/20/2026Revised

    Coverage Criteria for IL-6 Inhibitors

    Initial Therapy - Tocilizumab products

    Covered when ALL of the following per listed indication are met (grouped by indication below).

    Giant cell arteritis (Actemra and biosimilars): A. Individual is 18 years of age or older with GCA; AND B. Tocilizumab is used in combination with a tapering course of corticosteroids (such as prednisone) OR C. Tocilizumab is used as a single agent following discontinuation of corticosteroids
    Rheumatoid arthritis (Actemra and biosimilars): A. Individual is 18 years of age or older with moderate to severe RA; AND B. Individual has had an inadequate response to methotrexate titrated to maximally tolerated dose (ACR 2021) OR C. If methotrexate is not tolerated, individual has had an inadequate response to, or is intolerant of other conventional therapy (sulfasalazine, leflunomide, or hydroxychloroquine) OR D. Individual has a contraindication to methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine
    Polyarticular juvenile idiopathic arthritis (PJIA): A. Individual is 2 years of age or older with moderate to severe PJIA; AND B. Individual has had an inadequate response to, or is intolerant of conventional therapy (nonbiologic DMARDs such as methotrexate) OR C. Individual has a contraindication to methotrexate
    Policy Summary
    PayerAnthem
    PolicyMonoclonal Antibodies to Interleukin-6
    Policy CodePolicy CC-0066
    Change TypeRevised — coding and clinical updates
    Effective Date03/26/2026
    Last ReviewFeb 20, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for initial and continuation requests and include indication-specific documentation (diagnosis, prior therapies, and product-specific details).
    SourceLink
    On This Page
    Coverage Criteria for IL-6 InhibitorsCoding, Dosing and Quantity LimitsPrior Authorization, Documentation and Provider ResponsibilitiesBackground and Clinical ContextDefinitions and Disease Descriptions
    Still's disease (AOSD or SJIA): A. Individual is 2 years of age or older with Still's Disease as either AOSD or SJIA
    Unicentric Castleman Disease: A. Diagnosis of relapsed/refractory or progressive unicentric Castleman Disease; AND B. Used as a single agent; AND C. Human immunodeficiency virus (HIV) negative; AND D. Human herpesvirus-8 (HHV-8) negative
    Cytokine Release Syndrome (CRS): A. Individual is 2 years of age or older with autologous T cell immunotherapy-related CRS OR B. Individual has acute lymphocytic leukemia and is using tocilizumab for severe blinatumomab-induced CRS OR C. Individual is using tocilizumab as prophylaxis prior to first dose of any bispecific antibody to reduce risk of CRS
    Chronic Antibody-Mediated Renal Transplant Rejection (cAMR): A. Chronic active antibody-mediated rejection plus donor-specific antibodies and transplant glomerulopathy; AND B. Individual has failed to respond to intravenous immune globulin (IVIG) plus rituximab therapy (with or without plasma exchange)
    Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): A. Diagnosis of SSc-ILD; AND B. HRCT showing ground glass opacification or fibrosis; AND C. Pulmonary function tests demonstrating Forced Vital Capacity (FVC) > 55% predicted
    COVID-19 (hospitalized): A. Individual is 2 years of age or older; AND B. Individual is currently hospitalized with COVID-19; AND C. Individual is currently receiving systemic corticosteroids and requires supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)
    Acute Graft-versus-host disease (GVHD): A. Steroid-refractory acute GVHD; AND B. Initiating tocilizumab in combination with systemic corticosteroids
    Immunotherapy-related toxicities: A. Individual is undergoing immune checkpoint inhibitor therapy for a cancer diagnosis; AND B. Using tocilizumab for one of: giant cell arteritis, moderate to severe inflammatory arthritis unresponsive to corticosteroids or nonbiologic DMARDs, or steroid-refractory polymyalgia rheumatica (NCCN 2A)
    Other indicated conditions: Refractory/progressive KSHV-associated Inflammatory Cytokine Syndrome (KICS) (NCCN 2A); Multicentric Castleman disease progressing after prior therapy (NCCN 2A)

    Initial and continuation therapy - Kevzara

    Covered when ALL of the following are met for rheumatoid arthritis or other specified indications.

    Rheumatoid arthritis (Kevzara): A. Individual is 18 years of age or older with moderately to severe RA; AND B. Individual has had an inadequate response to methotrexate titrated to maximally tolerated dose (ACR 2021) OR C. If methotrexate is not tolerated, individual has had an inadequate response to, or is intolerant of other conventional therapy (sulfasalazine, leflunomide, or hydroxychloroquine) OR D. Individual has a contraindication to methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine
    Continuation (Kevzara): I. Individual has been receiving and is maintained on a stable dose of Kevzara (sarilumab); AND II. There is clinically significant improvement or stabilization in clinical signs and symptoms of disease

    Continuation Therapy - Tocilizumab products

    Continuation requests may be approved when ALL of the following are met.

    Continuation (Actemra and biosimilars): I. Individual has been receiving and is maintained on a stable dose of Actemra, Avtozma, Tofidence, or Tyenne; AND II. There is clinically significant improvement or stabilization in clinical signs and symptoms of disease

    Coverage conditions and quantity limits

    Covered when product-specific and indication-specific clinical criteria and member benefit provisions are met; COVID-19 HCPCS codes require hospitalized patients receiving systemic corticosteroids and requiring supplemental oxygen or higher-level respiratory support.

    Tocilizumab COVID-19 hospitalization requirement: HCPCS M0233-M0249 and Q0235-Q0249 apply only for hospitalized patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMOhospitalized + systemic corticosteroids + oxygen/ventilation/ECMO

    See HCPCS code descriptions for product-specific assignment

    Quantity limit for subcutaneous tocilizumab products: Subcutaneous tocilizumab autoinjector or prefilled syringe (Actemra, Avtozma, Tyenne) limited to 4 autoinjectors or syringes per 28 days<=4 devices per 28 days

    Specific to 162 mg/0.9 mL presentations

    Quantity limit for sarilumab (Kevzara): Kevzara prefilled pen or syringe limited to 2 pens/syringes per 28 days<=2 devices per 28 days

    150 mg and 200 mg presentations

    Requests for IL-6 receptor monoclonal antibodies used in combination with certain other immunomodulatory therapies are not approved. Specifically, use of IL-6 inhibitors in combination with topical or oral JAK inhibitors, ozanimod, etrasimod, deucravacitinib, nintedanib, or the listed biologic immunomodulators (including but not limited to TNF antagonists, IL-23 inhibitors, IL-17 inhibitors, vedolizumab, ustekinumab, abatacept, IL-1 inhibitors, other IL-6 inhibitors, rituximab, or natalizumab) is not approved and will not meet coverage criteria.

    Recent policy revisions updated the exclusion and combination lists. The 02/20/2026 document history notes removal of pirfenidone from the prohibited combination list and removal of selected exclusions (for example, tuberculosis and other select exclusions). The history also documents coding updates to HCPCS assignments for tocilizumab biosimilars and Tyenne effective on the dates indicated.

    Requests that do not satisfy the indication-specific medical necessity criteria described elsewhere in this policy, or requests that propose combining IL-6 inhibitors with the prohibited agents listed above, will not be approved and are considered not medically necessary.

    The lists of procedure, diagnosis, and device codes included in this policy are provided for informational purposes only. Inclusion or exclusion of a code does not by itself guarantee coverage; determination of coverage and reimbursement depends on the member's contract benefits and applicable prior authorization decisions at the time of service.

    Coding, Dosing and Quantity Limits

    Quantity limits by product and formulationmixedCovered
    Actemra (tocilizumab) IV vials 80 mg, 200 mg, 400 mgLimit = 8 mg/kg as frequently as every 4 weeks
    Avtozma (tocilizumab-anoh) IV vials 80 mg, 200 mg, 400 mgLimit = 8 mg/kg as frequently as every 4 weeks
    Tofidence (tocilizumab-bavi) IV vials 80 mg, 200 mg, 400 mgLimit = 8 mg/kg as frequently as every 4 weeks
    Tyenne (tocilizumab-aazg) IV vials 80 mg, 200 mg, 400 mgLimit = 8 mg/kg as frequently as every 4 weeks
    Actemra 162 mg/0.9 mL autoinjector or prefilled syringeLimit = 4 autoinjectors or syringes per 28 days
    Avtozma 162 mg/0.9 mL autoinjector or prefilled syringeLimit = 4 autoinjectors or syringes per 28 days
    Tyenne 162 mg/0.9 mL autoinjector or prefilled syringeLimit = 4 autoinjectors or syringes per 28 days
    Kevzara (sarilumab) 150 mg, 200 mg prefilled pen/syringeLimit = 2 pens/syringes per 28 days
    Tocilizumab Agents - J/Q codesHCPCSCovered
    J3262Injection, tocilizumab, 1 mg [Actemra subcutaneous (tocilizumab)]
    J3590Unclassified biologics [when specified as Actemra subcutaneous (tocilizumab)]
    Q5133Injection, tocilizumab-bavi (Tofidence), biosimilar, 1 mg
    Q5135Injection, tocilizumab-aazg (Tyenne), biosimilar, 1 mg
    Q5156Injection, tocilizumab-anoh (Avtozma), biosimilar, 1 mg
    Kevzara HCPCSHCPCS
    C9399Unclassified drugs or biologicals (Hospital Outpatient Use ONLY) [when specified as Kevzara (sarilumab)]
    J3590Unclassified biologics [when specified as Kevzara (sarilumab)]
    Tocilizumab COVID-19 specific HCPCSHCPCSCovered
    M0233Intravenous infusion, tocilizumab-aazg, for hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO, includes
    M0234Intravenous infusion, tocilizumab-aazg, for hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO, includes
    M0235Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of COVID-19 ... first dose [when specified as Tofidence (tocilizumab-bavi)]
    M0236Intravenous infusion, monoclonal antibody products ... second dose
    M0237Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with COVID-19 ... includes
    M0238Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with COVID-19 ... includes
    M0249Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO only, includes infusion and post administration monitoring
    M0250Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years and older) with COVID-19 ... second dose [Actemra IV 2nd dose administration]
    Q0235Injection, monoclonal antibody products with an indication of post-exposure prophylaxis or treatment of COVID-19 ... 1 mg [when specified as Tofidence (tocilizumab-bavi)]
    Q0237Injection, tocilizumab-anoh, for hospitalized adult patients with COVID-19 ... 1 mg [Avtozma]
    1–10 of 12
    1/2
    ICD-10 Diagnoses associated with coverageICD-10
    J12.82Pneumonia due to coronavirus disease 2019
    U07.1COVID-19
    M05.00-M05.ARheumatoid arthritis with rheumatoid factor
    M06.00-M06.09Rheumatoid arthritis without rheumatoid factor
    M06.4Inflammatory polyarthropathy
    M06.80-M06.89Other specified rheumatoid arthritis
    M06.9Rheumatoid arthritis, unspecified
    M08.00-M08.9AJuvenile arthritis
    M31.5Giant cell arteritis with polymyalgia rheumatica
    M31.6Other giant cell arteritis
    1–10 of 19
    1/2
    CPT copyright noticemixed
    © CPT OnlyAmerican Medical Association copyright statement for CPT
    IV dosing maximum per dose
    IV dosing maximum per doseUp to 8 mg/kg per dose (weight‑based IV dosing). Dose caps apply: for rheumatoid arthritis, cytokine release syndrome, and COVID‑19 each dose should not exceed 800 mg total; for giant cell arteritis each dose should not exceed 600 mg total. Indication‑specific overrides exist for pediatric JIA and CRS as described in override criteria (higher mg/kg and dosing frequency).
    PJIA overrideMay approve up to 10 mg/kg every 4 weeks for individuals weighing <30 kg.
    SJIA overrideMay approve up to 12 mg/kg every 2 weeks for patients <30 kg and up to 8 mg/kg every 2 weeks for patients ≥30 kg.
    CRS dosing allowanceFor CRS, may approve up to four IV doses (each up to 8 mg/kg if ≥30 kg or up to 12 mg/kg if <30 kg) given at least 8 hours apart.
    COVID‑19 dosing allowanceFor hospitalized COVID‑19, may approve up to two IV doses (each up to 8 mg/kg if ≥30 kg or up to 12 mg/kg if <30 kg) given at least 8 hours apart; dose caps per indication still apply.
    Subcutaneous dispensing frequency
    Actemra / Avtozma / Tyenne (subcutaneous)Dispense up to 4 autoinjectors or prefilled syringes per 28 days (162 mg/0.9 mL presentations).
    Kevzara (sarilumab)Dispense up to 2 prefilled pens or syringes per 28 days (150 mg or 200 mg presentations).
    Frequency basisQuantity limits are specified per 28‑day period and tied to the product's 162 mg (tocilizumab) or 150/200 mg (sarilumab) presentations.
    Quantity limits per 28 days
    Tocilizumab (Actemra / Avtozma / Tyenne) subcutaneousQuantity limit = 4 autoinjectors or 4 prefilled syringes per 28 days (162 mg/0.9 mL).
    Kevzara (sarilumab) prefilled pen/syringeQuantity limit = 2 pens or 2 prefilled syringes per 28 days (150 mg or 200 mg).
    Limit applicationLimits apply to the listed product presentations and are enforced on a 28‑day dispensing cycle.

    Prior Authorization, Documentation and Provider Responsibilities

    Prior Authorization

    Prior Authorization Required

    Prior authorization required per indication — Prior authorization is required for initial and continuation requests. Approvals are granted only when indication‑specific clinical criteria (including age, diagnosis, prior therapies, and objective testing where applicable) are met. Coverage is contingent on the member's contract and benefit limitations; inclusion of a code in this policy does not guarantee member coverage.

    • Prior authorization required for all indications listed unless otherwise specified in the member’s benefit plan.
    • Approvals granted when indication‑specific criteria in the policy are documented and met.
    • Inclusion of a procedure, diagnosis or device code in this document is informational and does not determine member coverage — verify member benefits prior to authorization.
    Step Therapy

    Guideline‑Directed Step Therapy and Prior Therapy Documentation

    Guideline‑directed step therapy and prior therapy documentation — Therapy decisions should follow guideline recommendations (for example, ACR guidance for rheumatoid arthritis: DMARD monotherapy with methotrexate titrated to maximally tolerated dose prior to biologic or JAK inhibitor use). Providers must document prior therapies, intolerance, contraindications, or inadequate response as required for the specific indication.

    • Documented trial and inadequate response to methotrexate titrated to maximally tolerated dose when required (or documented intolerance/contraindication to methotrexate and other conventional DMARDs when allowed).
    • For indications that require prior therapies (e.g., failure of IVIG plus rituximab for chronic antibody‑mediated renal transplant rejection), provide dates, doses, duration and response.
    • Biosimilar step therapy: when applicable, step therapy may require use of a biosimilar; exception allowed for interchangeable biosimilars per policy updates (see coding/step therapy section).
    Documentation Required

    Diagnosis and Prior Therapy Documentation

    Diagnosis and prior therapy documentation required for authorization — Providers must submit documentation that supports the requested indication and demonstrates prior therapy trials or failures where specified. Records should include relevant history, prior medication names, dosing, dates, clinical response, and reasons for discontinuation (e.g., intolerance, adverse events, lack of efficacy).

    • Provide medical records, clinic notes, or summaries showing diagnosis and meeting of clinical criteria in the policy.
    • Document prior medication trials (start/stop dates, doses, reason for discontinuation) when required by the indication.
    • For requests citing prior biologic or immunomodulator use, include concurrent medication lists and rationale for switching or combining if applicable.
    Documentation Required

    SSc‑ILD Imaging and PFT Documentation

    SSc‑ILD imaging and pulmonary function testing documentation — For Systemic Sclerosis‑Associated Interstitial Lung Disease (SSc‑ILD) requests, providers must supply objective imaging and PFT data demonstrating disease characteristics and eligibility.

    • Chest high‑resolution CT (HRCT) report demonstrating ground glass opacification or fibrosis consistent with SSc‑ILD.
    • Pulmonary function testing showing Forced Vital Capacity (FVC) > 55% of predicted as required by the criteria (include test date and numeric values).
    • Include clinical correlation and treating clinician notes describing disease course and rationale for tocilizumab use in SSc‑ILD.
    Documentation Required

    Documentation for Authorization

    Documentation for authorization and provider responsibilities — Supply complete supporting documentation to facilitate timely review. The Plan may perform history and coding reviews; incomplete or missing documentation may delay or result in denial.

    • Submit diagnosis‑specific documentation and product‑specific information (drug, route, dose, and billing code) with the authorization request.
    • Be prepared to provide operative reports, infusion records, or prior authorization determinations if requested.
    • The Plan may review coding and historical revisions when processing requests; administrative or coding updates in the document history may affect authorization handling.
    Note

    Override and Precedence

    Override and precedence — Federal and state laws, contract language, or other Plan utilization management programs may override or take precedence over the clinical criteria in this policy. When conflicts exist, the applicable law, regulation, or contract language governs.

    • If state or federal mandates require coverage different from this policy, those mandates supersede the policy criteria.
    • Provider should verify applicable contractual provisions and state/federal requirements when submitting an authorization request.
    Note

    Copyright / Reproduction

    Copyright and reproduction — The content of this publication is protected. Reproduction, storage, or transmission in any form without permission from the health plan is prohibited.

    • No part of this publication may be reproduced, stored in a retrieval system or transmitted by any means without permission from the health plan.
    • © CPT Only - American Medical Association

    Background and Clinical Context

    Interleukin-6 receptor monoclonal antibodies act by inhibiting IL-6 signaling and are used to treat multiple inflammatory and immune-mediated conditions. These agents are approved for disorders including rheumatoid arthritis, giant cell arteritis, various juvenile idiopathic arthritis subtypes (including systemic and polyarticular forms), and cytokine release syndrome, and are also used in select refractory conditions such as systemic sclerosis–associated interstitial lung disease (SSc-ILD) and chronic antibody-mediated renal transplant rejection where standard therapies have failed. Some indications have conditional or limited supporting evidence and require documentation of prior therapies or specific diagnostic testing (for example, HRCT and PFTs for SSc-ILD).

    Definitions and Disease Descriptions

    Systemic juvenile idiopathic arthritis (SJIA)
    DefinitionSystemic juvenile idiopathic arthritis (SJIA) is an autoinflammatory condition marked by intermittent fever, rash, and arthritis.
    Guideline treatment optionsACR guidance: initial therapy may include NSAIDs or glucocorticoids; IL‑1 inhibitors (anakinra or canakinumab) or tocilizumab are conditionally recommended and may be used for inadequate response or intolerance to initial therapy.
    Age considerationsSJIA recommendations and dosing considerations apply to pediatric patients; overrides for tocilizumab dosing in SJIA are specified for patients <30 kg.
    Giant cell arteritis (GCA)
    DefinitionGiant cell arteritis (GCA) is vasculitis of large‑ and medium‑sized vessels occurring primarily in individuals >50 years of age and is commonly associated with polymyalgia rheumatica.
    Primary treatmentPrimarily treated with systemic corticosteroids; tocilizumab is approved for GCA and is initiated with a tapering course of corticosteroids and continued as monotherapy per guidance.
    Dosing cap for GCAFor IV tocilizumab in GCA, each dose should not exceed 600 mg total (dose cap).
    Cytokine release syndrome (CRS)
    TermCytokine release syndrome (CRS)
    Associated codingCRS maps to ICD‑10 codes D89.831–D89.839 and R65.10–R65.11 in the policy coding lists.
    Dosing guidanceFor CRS, tocilizumab IV may be approved for up to four doses at least 8 hours apart; dosing may be up to 8 mg/kg for individuals ≥30 kg and up to 12 mg/kg for individuals <30 kg (see IV override criteria).